Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.82 USD | -5.87% | -25.84% | +17.03% |
04-17 | North American Morning Briefing : Stock Futures -2- | DJ |
04-16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.03% | 11.88M | |
+18.71% | 47.02B | |
+48.77% | 41.86B | |
+0.37% | 41.76B | |
-4.27% | 28.8B | |
+11.81% | 26.05B | |
-22.27% | 19.15B | |
+4.34% | 12.55B | |
+29.31% | 12.34B | |
-3.92% | 11.82B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Cerecor : Oppenheimer Adjusts Cerecor PT to $7 From $9 on Q1 Results and Ahead of Top-Line Data, Maintains Outperform Rating